Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.

Magnetic Resonance–Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson’s Disease: A Pilot Study

Nico Golfré Andreassi, MD,1*  Roberto Cilia, MD,1†  Luigi Michele Romito, PhD,1  Salvatore Bonvenga, MD,1  Giulia Straccia, MD,1  Antonio Emanuele Elia, PhD,1  Alessio Novelli, MD,1  Giuseppe Messina, MD,2  Giovanni Tringali, MD,2  Vincenzo Levi, MD,2  Grazia Devigili, PhD,1  Sara Rinaldo, Tch,1  Valentina Gasparini, MD,1  Marina Grisoli, MD,2  Mario Stanziano, MD,3,4  Francesco Ghielmetti, MSc,5  Sara Prioni, MSc,6  Elisa Bocchi, MSc,6  Paolo Amami, MSc,6  Sylvie Hélène Marie Jeanne Piacentini, PhD,6  Elisa Francesca Maria Ciceri, MD,7  Maria Grazia Bruzzone, MD,3  and Roberto Eleopra, MD1  

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Dr. Roberto Cilia, Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, via G. Celoria 11, 20133 Milan, Italy. E-mail: roberto.cilia@istiobesta.it

Relevant conflicts of interest/financial disclosures: Nothing to report.

Full financial disclosures and author roles may be found in the online version of this article.

Received: 19 February 2022; Revised: 10 May 2022; Accepted: 6 June 2022

Published online 29 August 2022 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29200
The thalamic nucleus ventralis intermedius (VIM) is a widely used target for the surgical treatment of medication-resistant tremor in patients with essential tremor (ET) and Parkinson’s disease (PD). Recently, the ablative procedure gained renewed interest because of the introduction in clinical practice of magnetic resonance–guided focused ultrasound (MRgFUS), which allows to ablate deep brain structures through thermal coagulation without opening the skull.  

To date, MRgFUS VIM thalamotomy has been mostly focused on ET and proved to be safe and effective. Studies on the effects of MRgFUS VIM thalamotomy in PD are, on the contrary, still scarce. To our knowledge, only one randomized clinical trial has been published, showing improvement of tremor lasting for 1 year. Overall, the outcome of MRgFUS thalamotomy has been described in less than 100 patients with tremor-dominant PD.

Pharmacological treatment of tremor in PD may be challenging because this symptom may be levodopa resistant or show a “pseudoresistance” requiring higher dosages of dopaminergic medications than other cardinal symptoms. However, increasing dopaminergic medications may lead to adverse effects (AEs), such as increasing the risk for impulse control disorder (ICD) or motor fluctuations and dyskinesias. To our knowledge, no study specifically investigated whether MRgFUS VIM thalamotomy may allow a sustained reduction of dopaminergic therapy dosage and thus be considered a modern “dopaminergic therapy–sparing strategy” in tremor-dominant PD.

We hypothesized that MRgFUS thalamotomy may be performed at the earliest stages of tremor-dominant PD aiming to “spare” dopaminergic medications and thus reduce the risk associated with the progressive increase of oral medical therapy over time.

In this study, the primary objective was to demonstrate that MRgFUS VIM thalamotomy performed in patients with early-stage tremor-dominant PD is associated with a significantly lower dopaminergic therapy daily dosage after 6 months compared with a matched PD control population on standard medical therapy.

Subjects and Methods

We included patients diagnosed with early-stage idiopathic PD and tremor-dominant clinical phenotype who underwent MRgFUS VIM thalamotomy (PD-FUS) between February 1, 2019, and March 31, 2021, and with at least one follow-up visit ≥6 months after the procedure. Early-stage PD was defined as follows: total duration of dopaminergic therapy between 6 months and 4 years and no history of motor fluctuations or dyskinesias. MRgFUS eligibility criteria, which comprises the presence of medication-refractory tremor, are detailed in Supporting Information Material 1.

Data from PD-FUS were compared with those of a control group of patients with tremor-dominant PD treated with oral dopaminergic therapy (PD-ODT), matched by sex, age, and disease duration in a 1:2 ratio. In the PD-ODT group, we included patients who met inclusion criteria but did not undergo MRgFUS.

All patients were visited by neurologists expert in movement disorders, who assessed motor performance

ABSTRACT: Background: Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is a safe and effective procedure for drug-resistant tremor in Parkinson’s disease (PD).

Objective: The aim of this study was to demonstrate that MRgFUS ventralis intermedius thalamotomy in early-stage tremor-dominant PD may prevent an increase in dopaminergic medication 6 months after treatment compared with matched PD control subjects on standard medical therapy.

Methods: We prospectively enrolled patients with early-stage PD who underwent MRgFUS ventralis intermedius thalamotomy (PD-FUS) and patients treated with oral dopaminergic therapy (PD-ODT) with a 1:2 ratio. We collected demographic and clinical data at baseline and 6 and 12 months after thalamotomy.

Results: We included 10 patients in the PD-FUS group and 20 patients in the PD-ODT group. We found a significant increase in total levodopa equivalent daily dose and levodopa plus monoamine oxidase B inhibitors dose in the PD-ODT group 6 months after thalamotomy.

Conclusions: In early-stage tremor-dominant PD, MRgFUS thalamotomy may be useful to reduce tremor and avoid the need to increase dopaminergic medications. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Key Words: Parkinson’s disease; tremor; thalamotomy; VIM; MRgFUS

The thalamic nucleus ventralis intermedius (VIM) is a widely used target for the surgical treatment of medication-resistant tremor in patients with essential tremor (ET) and Parkinson’s disease (PD). Recently, the ablative procedure gained renewed interest because of the introduction in clinical practice of magnetic resonance–guided focused ultrasound (MRgFUS), which allows to ablate deep brain structures through thermal coagulation without opening the skull.

To date, MRgFUS VIM thalamotomy has been mostly focused on ET and proved to be safe and effective. Studies on the effects of MRgFUS VIM thalamotomy in PD are, on the contrary, still scarce. To our knowledge, only one randomized clinical trial has been published, showing improvement of tremor lasting for 1 year. Overall, the outcome of MRgFUS thalamotomy has been described in less than 100 patients with tremor-dominant PD.

Pharmacological treatment of tremor in PD may be challenging because this symptom may be levodopa resistant or show a “pseudoresistance” requiring higher dosages of dopaminergic medications than other cardinal symptoms. However, increasing dopaminergic medications may lead to adverse effects (AEs), such as increasing the risk for impulse control disorder (ICD) or motor fluctuations and dyskinesias. To our knowledge, no study specifically investigated whether MRgFUS VIM thalamotomy may allow a sustained reduction of dopaminergic therapy dosage and thus be considered a modern “dopaminergic therapy–sparing strategy” in tremor-dominant PD.

We hypothesized that MRgFUS thalamotomy may be performed at the earliest stages of tremor-dominant PD aiming to “spare” dopaminergic medications and thus reduce the risk associated with the progressive increase of oral medical therapy over time.
| Demographic characteristics | Baseline P value a (differences at baseline) | 6 months Change from baseline (%) b | Change from baseline (%) b |
|-----------------------------|--------------------------------------------|------------------------------------|---------------------------|
|                             | PD-FUS | PD-ODT | PD-FUS | PD-ODT | PD-FUS | PD-ODT | PD-FUS | PD-ODT |
| Sex (M/F)                   | 8/2    | 16/4    |        |        | 15.5 (10.0; 20.0) | 23.9 (18.5; 29.9) | −34.4 (−50.0; −12.0) | −18.0 (−22.9; 2.0) |
| Age (y)                     | 62.3 (60.2; 72.3) | 62.87 (59.5; 72.1) | 0.895  | 7.0 (5.0; 10.3) | 63.3 (55.2; 82.5) | 3.8 (−2.7; 25.0) | <0.001 |
| Disease duration (y)        | 3.8 (2.4; 4.5) | 3.2 (2.8; 4.0.1) | 0.936  | 2.5 (1.0; 5.0) | 90.0 (17.9; 100.0) | 25.0 (0.0; 66.7) | 0.196 |
| Time to surgery (mo)        | 2.5 (1.7; 4.2) | NA      |        |        | 6.3 (5.0; 6.7) | 7.4 (5.5; 8.6) |          |          |
| Time to follow-up visit (mo)|        |         |        |        |          |          |          |          |
| Demographic characteristics |        |         |        |        |          |          |          |          |
| Motor outcome (on medication) |        |         |        |        |          |          |          |          |
| MDS-UPDRS-III total score d| 22.5 (17.0; 28.0) | 27.8 (20.3; 32.9) | 0.102  | 15.5 (10.0; 20.0) | 23.9 (18.5; 29.9) | −34.4 (−50.0; −12.0) | −18.0 (−22.9; 2.0) |
| Tremor d                    | 8.0 (7.0; 9.8) | 8.0 (6.0; 11.3) | 0.691  | 3.0 (1.5; 4.8) | 7.0 (5.0; 10.3) | 63.3 (55.2; 82.5) | 3.8 (−2.7; 25.0) | <0.001 |
| Rigidity d                  | 2.0 (2.0; 3.0) | 4.0 (3.0; 6.3) | 0.012  | 0.5 (0.0; 2.0) | 2.5 (1.0; 5.0) | 90.0 (17.9; 100.0) | 25.0 (0.0; 66.7) | 0.196 |
| Bradykinesia d              | 6.5 (4.5; 8.75) | 8.0 (7.0; 12.0) | 0.069  | 6.0 (3.0; 6.8) | 8.0 (5.8; 11.0) | 0.0 (0.0; 22.3) | 15.9 (0.0; 28.6) | 0.534 |
| H&Y26                       | 2 (1; 2) | 2 (1; 2) | 1      | 2 (1; 2) | 2 (2.2) | 0 (0; 0) | 0 (0; 0) | 0.235 |
| Dopaminergic medications    |        |         |        |        |          |          |          |          |
| Duration (y)                | 1.9 (1.3; 2.6) | 2.5 (2.2; 3.4) | 0.148  |        |          |          |          |          |
| Total LEDD (mg/d)          | 472.5 (300.0, 650.0) | 400.0 (285.0; 525.0) | 0.897  | 497.5 (300.0; 600.0) | 527.5 (406.3; 632.5) | 0.0 (−20.6; 16.0) | 24.7 (9.0; 65.2) | 0.017 |
| Levodopa + MAOB-Is dose (mg/d) e | 350.0 (100.0; 500.0) | 275.0 (100.0; 500.0) | 0.756  | 325.0 (200.0; 462.5) | 375.0 (250.0; 575.0) | 0.0 (−12.5; 33.3) | 17.5 (0.0; 50.0) | 0.400 |
| Patients on levodopa and/or MAOB-Is, n (%) | 7 (70%) | 18 (90%) | 0.300  | 8 (80%) | 19 (95%) |          |          |          |
| DA dose (mg/d) f            | 165.0 (150.0; 360.0) | 120.0 (75.0; 300.0) | 0.069  | 150.0 (120.0; 300.0) | 120.0 (80.0; 240.0) | −10.00 (−33.3; 0.0) | 0.0 (0.0; 0.0) | 0.051 |
| Patients on DA, n (%)       | 10 (100%) | 14 (70%) | 0.074  | 10 (100%) | 17 (85%) |          |          |          |

Data are expressed as median (interquartile range) unless otherwise specified.

PD-FUS, patients with Parkinson’s disease treated with magnetic resonance–guided focused ultrasound; PD-ODT, patients with Parkinson’s disease treated with oral dopaminergic therapy; M, male; F, female; MDS-UPDRS-III, Movement Disorder’s Society Unified Parkinson’s Disease Rating Scale–motor Part III; H&Y, Hoehn and Yahr stage; LEDD, levodopa equivalent daily dose; MAO-I, monoamine oxidase inhibitor; DA, dopamine agonist.

VIM MRgFUS ALLOWS THERAPY SPARING IN EARLY PD

Movement Disorders, Vol. 37, No. 11, 2022
We collected demographic and clinical data at baseline, 6 months, and 12 months after surgery.

Dopaminergic drug therapy was calculated as levodopa equivalent daily dose (LEDD). Total LEDD and LEDD associated separately with levodopa and monoamine oxidase B inhibitors (MAOBI) or dopamine agonists (DAs) were computed.

Change between baseline and follow-up visits of MDS-UPDRS-III and LEDD were computed and expressed as percentage of change from baseline.

AEs were extensively collected for both groups; for PD-FUS, we also collected AEs associated with thalamotomy and with MRI environment or ultrasonography procedure.

MRgFUS VIM thalamotomy screening and procedure were approved by the local Ethics Committee (CE n.59/2020). All patients gave their written informed consent to the use of their anonymized clinical data for research purposes.

Details about the statistical analyses are reported in Supporting Information Material 1.

Results

A total of 145 patients with tremor-dominant PD were initially evaluated and referred to a dedicated outpatient clinic for the evaluation for MRgFUS thalamotomy. Eighty-nine patients were accepted to undergo the full screening evaluations for MRgFUS VIM thalamotomy, of whom 37 underwent the procedure. Of these 37, we included 10 patients with early-stage PD who fulfilled our a priori defined criteria.

Among the 108 patients who were treated only with optimized drug therapy, 20 matched PD-ODT were selected and included in the analysis. Details about the causes of exclusion are reported in Fig. S1.

Baseline demographic and clinical features were similar between PD-FUS and PD-ODT (Table 1).

At 6-month follow-up, we observed a significant difference in total LEDD between the two groups, because of increased LEDD in the PD-ODT group versus stable dosage in PD-FUS (Table 1, Fig. 1A).

FIG. 1. Change in dopaminergic medications and motor outcome between baseline and 6-month follow-up in patients with Parkinson’s disease (PD) treated with magnetic resonance–guided focused ultrasound (PD-FUS; n = 10) and patients with PD treated with oral dopaminergic therapy (PD-ODT, n = 20). Dopaminergic medications are reported as levodopa equivalent daily dose (LEDD) and divided as total LEDD (A), LEDD of levodopa plus monoamine oxidase inhibitors (MAO-Is) (B) and LEDD of dopamine agonists (LEDD DAs) (C). The motor outcome (D) is expressed with the Movement Disorders Society Unified Parkinson’s Disease Rating Scale-motor Part III (MDS-UPDRS-III; ranging from 0 to 132, with greater scores indicating greater severity). Paired Student t test or Wilcoxon test was applied depending on normality of the data. *P < 0.05; **P < 0.01.
We found a significant increase in total LEDD and LEDD of levodopa plus MAOB-I in the PD-ODT group ($P = 0.001$ and $P = 0.014$) and a mild reduction in LEDD of DA in the PD-FUS group ($P = 0.042$) (Fig. 1A–C).

In both groups, we observed a reduction in MDS-UPDRS-III motor score at the 6-month follow-up (Fig. 1, Table 1). However, the change was significantly higher in PD-FUS than PD-ODT, which was due to improvement in tremor in the former group (Table 1). Notably, the reduction in MDS-UPDRS-III between baseline and 6-month follow-up was statistically significant only for the PD-FUS group ($P = 0.002$), while in the PD-ODT group there was only a trend to a statistically significant difference ($P = 0.081$) (Fig. 1D).

At 12-month follow-up, we found similar results despite the much-reduced sample size (PD-FUS, $n = 4$; PD-ODT, $n = 8$). Details are reported in Table S1 and Fig. S2. Indeed, total LEDD change was still significantly different between the two groups ($P = 0.01$), with a significant increase in total LEDD and LEDD of levodopa plus MAOB-I in the PD-ODT group after 12 months compared with baseline ($P = 0.005$ and $P = 0.042$, respectively) (Fig. S2A,B).

**Safety**

AEs are detailed in Table S2. No serious AEs (ie, associated with new or prolonged hospitalization, permanent disability, or death) were found in either PD-FUS or PD-ODT; overall, no statistically significant differences were found in the AEs profile between PD-FUS and PD-ODT.

**Discussion**

MRgFUS thalamotomy is a safe and effective treatment for tremor in patients with PD.$^6$ In the present pilot study, our findings suggest that MRgFUS thalamotomy performed in patients with early-stage tremor-dominant PD allows to maintain low daily dosage of oral dopaminergic medications along with a good control of tremor for at least 6 months.

Management of dopaminergic therapy has never been specifically investigated by studies reporting data on MRgFUS thalamotomy in PD. In a recent clinical trial, Bond et al.$^6$ found a tendency to decrease dopaminergic medication in patients with PD treated with MRgFUS thalamotomy compared with an increase in patients who underwent the sham procedure; however, this trial was not designed to investigate this phenomenon, and the authors do not comment on this finding. Recently, Sinai et al.$^{13}$ suggested that MRgFUS VIM thalamotomy may delay initiation of levodopa treatment, and Yamamoto et al.$^{14}$ found a stabilization or increase in dopaminergic therapy after 1-year follow-up. In other studies, change in LEDD after MRgFUS VIM thalamotomy was not reported.$^{9,10,12,27}$ A previous study on stereotactic thalamotomy found a dramatic and long-lasting reduction in dopaminergic medication$^{28}$; more than half of these patients were, however, on Hoehn and Yahr stage III or IV, and direct comparison with our early-stage PD population may be unreliable.

We found a stabilization of LEDD in PD-FUS after VIM thalamotomy; differences in the study population, such as higher mean disease duration, motor score, and LEDD in the study of Bond et al.$^6$ may explain the different results. Moreover, in early-stage PD, it has been already shown that even deep brain stimulation of the subthalamic nucleus may not allow reduction of dopaminergic medications,$^{23,29}$ as opposed to deep brain stimulation of the subthalamic nucleus in patients with PD with motor complications.$^{30,31}$ It is therefore conceivable that unilateral VIM thalamotomy, which mainly improves tremor and no other cardinal features, may not allow dopaminergic therapy reduction in an early stage of the disease. The slight reduction in LEDD-DA dose in the PD-FUS group may not be clinically significant; for example, it has been shown that management for ICD required, on average, a reduction of more than 50% of the dosage of DAs.$^{32}$ In an available trial on interventional therapy in patients with early-stage PD, LEDD was increased during the study period in patients treated with only dopaminergic medications,$^9$ as we observed in our study. Effective control of tremor in PD often requires higher doses of dopaminergic medication than rigidity and bradykinesia. Our data confirm that patients with early tremor-dominant PD are likely to be treated with an increasingly high levodopa dose in an attempt to control their disabling tremor, with poor benefit. Dopaminergic medication can have behavioral side effects,$^{17}$ and a higher cumulative levodopa exposure has been linked to the development of motor fluctuations and dyskiniesias.$^{19}$ We can speculate that treatments that improve motor symptoms without the need to increase dopaminergic therapy may delay or reduce the incidence of these side effects.$^{17,33}$

In all studies, the MDS-UPDRS-III score decreased significantly shortly after the procedure (eg, 1 month$^{6,9}$) with an improvement lasting for 3,$^{6,10}$ 6,$^{9}$ and 12 or more months.$^{9,13,27}$ In our study, the reduction in the total motor score, despite being clinically and statistically significant, appears to be inferior to that previously reported; in previous works, a nearly 50% reduction in the total UPDRS motor score after the procedure was noted$^{6,9,10,27}$ while we noted a median 34.4% improvement in the MDS-UPDRS-III score. The use of a different scale, in which more points are attributed to different aspects of tremor, and the differences in the study populations may explain this finding.
Conclusions

In patients with early-stage tremor-dominant PD, MRgFUS thalamotomy may be useful to reduce tremor and avoid, in the short term, the need to increase dopaminergic medications. These results may help to understand the correct timing to address patients for MRgFUS thalamotomy, a treatment that, at the time being, should be reserved to patients with proven medication-refractory tremor.

Prospective studies with larger cohorts are needed to confirm these findings and to understand whether this treatment may reduce the incidence of AEs and long-term motor complications of dopaminergic therapy. Longer follow-up may additionally provide helpful information on the difference in time to dyskinesias between the two groups.

Acknowledgment

Open access funding provided by BIBLIOSAN.
Digital Gait Biomarkers Allow to Capture 1-Year Longitudinal Change in Spinocerebellar Ataxia Type 3

Winfried Ilg, PhD,1,2* Björn Müller, MSc,1 Jennifer Faber, MD,3,4 Judith van Gaalen, MD,5 Holger Hengel, MD,2,6 Ina R. Vogt, MD,4 Guido Hennes,4 Bart van de Warrenburg, MD,5 Thomas Klockgether, MD,3,4 Ludger Schöls, MD,2,6 Matthias Synofzik, MD,2,6 and the ESMI Consortium

ABSTRACT: Measures of step variability and body sway during gait have shown to correlate with clinical ataxia severity in several cross-sectional studies. However, to serve as a valid progression biomarker, these gait measures have to prove their sensitivity to robustly capture longitudinal change, ideally within short time frames (eg, 1 year). We present the first multicenter longitudinal gait analysis study in spinocerebellar ataxias. We performed a combined cross-sectional (n = 28) and longitudinal (1-year interval, n = 17) analysis in Spinocerebellar Ataxia type 3 subjects (including seven preataxic mutation carriers). Longitudinal analysis showed significant change in gait measures between baseline and 1-year follow-up, with high effect sizes (stride length variability: P = 0.01, effect size rprb = 0.66; lateral sway: P = 0.007, rprb = 0.73). Sample size estimation for lateral sway indicates a required cohort size of n = 43 for detecting a 50% reduction of

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

*Correspondence to: Dr. Winfried Ilg, Section Computational Sensomotorics, Hertie Institute for Clinical Brain Research, Otfrid-Müller-Straße 25, 72076 Tübingen, Germany; E-mail: winfried.ilg@uninetuebingen.de

Received: 14 March 2022; Revised: 15 July 2022; Accepted: 10 August 2022

Published online 31 August 2022 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29206